Simmunome AI

Founded in 2019 and based in Montréal, Quebec, Simmunome Inc. addresses the >90% clinical trial failure rate by transforming physiological systems into biologically representative computational models. The platform — offered as both a SaaS product and white-glove service — integrates protein networks, multi-omics data, and clinical evidence to provide target validation, patient stratification, and biomarker discovery. Key products include the BioTarget Scoring Tool (ranks drug target efficacy in seconds), Omic Signatures (identifies patient responders), and a Data Exploration Tool. The company's library covers 13 disease models across oncology, neurology, and metabolic disease, with more in development. Simmunome has been selected for the Merck Digital Sciences Studio accelerator and the Google for Startups Accelerator Canada program, and is trained under Mila's TRAIL AI ethics program.